Cryoniss
Cryoniss provides temperature-controlled biological sample storage and cold-chain logistics services — from ambient to -196°C — to UK and international pharmaceutical, biotechnology, CRO, and academic customers, operating as a Biofortuna Group subsidiary since May 2024.
- Company typePrivate
- Founded2018
- HeadquartersMacclesfield, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Cryoniss does
Cryoniss is a UK-based managed service provider delivering temperature-controlled biological sample storage and cold-chain logistics to the life sciences sector. The company stores biological samples across the full temperature spectrum: ambient, +4°C, -20°C, -80°C, and vapour phase liquid nitrogen (-196°C). Core services include biobanking, cell banking, cell culture services, cell line QC testing, clinical sample storage, bioreagent and diagnostic kit storage, medicinal product storage, investigational medicinal product (IMP) storage, and end-to-end cold-chain logistics. Facilities are located at Alderley Park (Macclesfield), The Heath Business and Technical Park (Runcorn), and Deeside (Wales), with international logistics handled through a GDP-compliant courier partner network.
The company operates under a B2B managed services and subscription model, charging per-sample monthly storage fees with no minimum volume, plus managed logistics and QC professional services fees. Go-to-market is enterprise field sales targeting pharma, biotech, clinical research organisations, and universities, supported by inbound content marketing and a published set of case studies across customer types from early-stage biotech (Lamellar Biomedical, Celentyx, Peak Proteins) through CROs (ApconiX, Medicines Discovery Catapult, Kinomica) to commercial-stage biotherapeutics and diagnostics (Revolo Biotherapeutics, PBD Biotech). The offering is differentiated by a stack of UK regulatory licences — MHRA WDA, HTA Research, HSE GMO Level 2, and APHA Category 2 — that allow customers to outsource regulated storage without securing licences individually, plus ISO 9001 / 21 CFR Part 11 monitoring and a 219-policy QMS.
Founded in 2018 (originally as Cryosphere Services, rebranded to Cryoniss in 2020) by former AstraZeneca leaders Sonia Houghton and Phil Hargreaves, the company raised GBP 500,000 from NPIF Maven Equity Finance in January 2022 and was acquired by Biofortuna Limited in May 2024, becoming part of the Biofortuna Group and operating as a wholly-owned subsidiary providing specialist bio-storage to the wider Biofortuna platform.
Cryoniss firmographics
Firmographics- Name
- Cryoniss
- Legal name
- Cryoniss Ltd
- Website
- https://cryoniss.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Cryoniss provides temperature-controlled biological sample storage and cold-chain logistics services — from ambient to -196°C — to UK and international pharmaceutical, biotechnology, CRO, and academic customers, operating as a Biofortuna Group subsidiary since May 2024.
- Ownership category
- akta.pro rank
Cryoniss industry classification
Industry- Product category
- Biological Sample Storage Services
- NAICS
- Refrigerated Warehousing and Storage (493120), Refrigerated Warehousing and Storage (49312)
- SIC
- Air-Cond & Warm Air Heatg Equip & Comm & Indl Refrig Equip (3585)
- akta.pro primary industry
- Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK)
- akta.pro secondary industries
- Cryogenic Logistics (LN2 Dry Shippers, -150°C) (HLAGAMAB), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN), Dry Ice & Cryogenic (LN2) Handling and Transport Services (TLACAMAM), Cryogenic / Ultra-Low Temperature Transport (e.g., dry ice, LN2) (TLADAHAJ)
Keywords
Where Cryoniss is headquartered
LocationHeadquarters
- HQ city
- Macclesfield
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Cryoniss business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Biological Sample Storage Services: Temperature-controlled storage services for biological samples from ambient through to cryogenic temperatures. Revenue generated through monthly/annual storage fees based on sample volume and temperature requirements.
- Cold-Chain Logistics Management: End-to-end logistics coordination including sample pickup, transport, customs clearance, and delivery with GDP-compliant supply chain management
- Cell Culture and QC Testing Services: Cell banking, cell culture services, and cell line quality control testing including mycoplasma testing through partner network
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Monthly | Pay-on-demand storage model |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Cryoniss product offering
Product offeringCore offering
Cryoniss provides temperature-controlled biological sample storage and end-to-end cold-chain logistics services across multiple temperature ranges (ambient, +4°C, -20°C, -80°C, and vapour phase liquid nitrogen at -196°C). The company serves pharmaceutical, biotechnology, academic, and clinical research organizations with regulated storage, biobanking, cell banking, cell culture, QC testing, and GDP-compliant logistics support.
Product overview
Cryoniss is a UK-based biological sample storage and logistics service provider offering a unified suite of temperature-controlled storage and cold-chain logistics services. The core offering encompasses biobanking, cell banking, cell culture services, cell line QC testing, clinical sample storage, bioreagent storage, medicinal product storage, investigational medicinal products storage, logistics support, and Covid-19 storage. Storage capabilities span ambient, +4°C, -20°C, -80°C, and vapour phase liquid nitrogen (-196°C) temperatures. The company serves sectors including blue sky research, pre-clinical, clinical, and market-approved products. In May 2024, Cryoniss was acquired by Biofortuna Group and now operates from Biofortuna's Deeside laboratories and The Heath Business and Technical Park in Runcorn.
Differentiator
Problem solved
Functional benefit
Products and services
- Biobanking Temperature-controlled biological sample storage service providing secure UK-based storage with next-day access to samples throughout the UK.
- Cell Banking Storage of master and archival cell banks in world-class facilities, ensuring cell line integrity and accessibility.
- Cell Culture Services Cell banks cultured to exceptional quality and consistency with next-day sample dispatch as standard.
- Cell Line QC Testing Routine quality control testing of cell lines ensuring high-quality reagents and data, including Mycoplasma testing services.
- Clinical Sample Storage Secure storage of clinical trial samples according to Good Clinical Practice (GCP) standards.
- Bioreagent Storage Storage of diagnostic and reagent kits keeping master stocks secure and fully traceable.
- Medicinal Product Storage Storage of medicinal products under MHRA Wholesale Distribution Authorisation ensuring product integrity and security.
- Investigational Medicinal Products Storage Storage and distribution support for investigational medicinal products (IMPs) in clinical trials, compliant with MHRA requirements.
- Logistics Support End-to-end cold chain logistics solutions including coordination of all sample and IMP logistics with Good Distribution Practice-compliant courier partners.
- Covid-19 Storage Storage solutions for Covid-19 samples, clinical trial samples for vaccines and therapeutics, and testing kits, with compliant logistics management.
Quantifiable outcome
- 100% sample handling accuracy achieved against Lean 6 Sigma target rate of 99.99966%
- +2 more outcomes
Companies that use Cryoniss
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
Cryoniss technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cryoniss partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and supporting.
- Biofortuna GroupflagshipCryoniss acquired by Biofortuna Limited in May 2024, becoming part of the Biofortuna family. Acquisition provides access to Biofortuna's Deeside laboratories and enables wider market reach across life sciences and biotech sectors. Cryoniss operations integrated with Biofortuna's world-class facilities.
- Perfectus BiomedcoreStrategic partnership for world-class cell culture services. Perfectus Biomed provides quality control testing including mycoplasma testing services, while Cryoniss manages logistics coordination for sample testing. Collaboration enables complete cell banking and QC testing service offering.
- A4P LogisticscoreGood Distribution Practice-compliant logistics partner providing seamless end-to-end cold chain service for international sample delivery and pickup. Partnership enables Cryoniss to offer comprehensive global logistics solutions with regulatory compliance.
- Tissue SolutionssupportingPartner for acquisition of Covid-19 positive samples for research purposes, enabling Cryoniss to offer complete sample acquisition and storage services during pandemic response efforts.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Cryoniss competitors and assessment
Company assessmentBroad incumbents
- Azenta Life Sciences (formerly Brooks Life Sciences): Azenta is a large global provider of sample management, biobanking, and cryogenic storage services for pharma and academic customers, with automated storage systems. It is directly comparable to Cryoniss' core biobanking and cold-chain offering but at materially greater scale and geographic reach.
- Thermo Fisher Scientific (Biobanking & Biorepository Services): Thermo Fisher offers a broad portfolio of biorepository, cryostorage, and bioservices solutions, including sample storage and cold-chain logistics for clinical trials and pharma. Comparable to Cryoniss' storage and GDP-compliant logistics but with a much larger, global service footprint.
- Charles River Laboratories: Charles River provides cell banking services, biologics testing, and biopharma support services including cryopreservation. Comparable in cell banking and QC testing services, with deeper scientific breadth and global reach.
- Lonza (Cell & Gene Services): Lonza operates a global cell and gene therapy manufacturing platform, including cryopreservation and cell banking services. Comparable to Cryoniss' vapour-phase LN2 storage and cell banking, with much larger scale and CDMO breadth.
- Eurofins Scientific (BioPharma Product Testing): Eurofins provides bioanalytical, biologics testing, and biopharma product testing services, with associated sample management and storage capabilities. Comparable in serving regulated pharma and biotech customers, though storage is a smaller part of its portfolio.
- Sartorius (Cell Banking & Bioprocess): Sartorius provides bioprocess and cell banking solutions used in upstream/downstream biomanufacturing, including cryopreservation consumables and services. Adjacent to Cryoniss' biological sample storage and cell banking activities, with broader bioprocessing exposure.
Others
- Biofortuna Limited: Biofortuna is Cryoniss' parent company (acquired May 2024) and a specialist CDMO and laboratory services provider with diagnostic kit and biologics capabilities. While not a direct competitor, it now houses Cryoniss' operations and is the relevant comparable for the integrated offering.
Direct peers
- Discovery Life Sciences: Discovery Life Sciences provides biospecimen acquisition, biobanking, and cell biology services for pharma, biotech, and diagnostics clients. Comparable to Cryoniss' biobanking, cell banking, and cell culture services with a US-centric but globally serving model.
- ReproCELL (now part of Axol Bioscience): ReproCELL specialises in cell banking, iPSC services, and cell-based assays for drug discovery, overlapping with Cryoniss' cell banking, cell culture, and biobanking offerings for life-sciences customers.
Regional players
- CellBank Australia (Children's Medical Research Institute): CellBank Australia is a specialist cell banking and cryopreservation provider serving the Australian/APAC research community, comparable in core function (cell line storage, GMP-aligned operations) to Cryoniss' cell banking service but focused on a different geography.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cryoniss social profiles
Digital presenceCryoniss compliance and trust
Trust signalCompliance12 records
Cryoniss financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cryoniss leadership team
Management profileNumber of profiles
Profiles8 records
Cryoniss funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cryoniss M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cryoniss
What does Cryoniss do?
Cryoniss provides temperature-controlled biological sample storage and end-to-end cold-chain logistics services across multiple temperature ranges (ambient, +4°C, -20°C, -80°C, and vapour phase liquid nitrogen at -196°C). The company serves pharmaceutical, biotechnology, academic, and clinical research organizations with regulated storage, biobanking, cell banking, cell culture, QC testing, and GDP-compliant logistics support.
Is Cryoniss a public or private company?
Cryoniss is a private company. It is classified as corporate owned and is currently acquired.
When was Cryoniss founded?
Cryoniss was founded in 2018. It employs 1 to 10 people.
Where is Cryoniss based?
Cryoniss is headquartered in Macclesfield, United Kingdom, in the Europe region.
How does Cryoniss make money?
Three revenue lines are on record. Biological Sample Storage Services are the primary driver. The others are cold-Chain Logistics Management and cell Culture and QC Testing Services.
Who are Cryoniss's main competitors?
Broad incumbents on record are Azenta Life Sciences (formerly Brooks Life Sciences), Thermo Fisher Scientific (Biobanking & Biorepository Services), Charles River Laboratories, Lonza (Cell & Gene Services), Eurofins Scientific (BioPharma Product Testing) and Sartorius (Cell Banking & Bioprocess). Biofortuna Limited is listed as an others. Direct peers are Discovery Life Sciences and ReproCELL (now part of Axol Bioscience). CellBank Australia (Children's Medical Research Institute) is listed as a regional player.
Does Cryoniss have an API?
No public API is recorded for Cryoniss.
What industry is Cryoniss in?
Cryoniss's product category is Biological Sample Storage Services. Its primary akta.pro industry code is HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low), with a secondary code of HLAGAMAB, Cryogenic Logistics (LN2 Dry Shippers, -150°C). Its NAICS code is 493120 and its SIC code is 3585.